Skip to main content

Table 5 Correlations between overall survival and various clinicopathological factors

From: The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer

 

Univariate analysis

Multivariate analysis

Hazard Ratio

95% CI

p-value

Hazard Ratio

95% CI

p-value

Location of primary tumor (Rectum)

0.786

0.452-1.369

0.395

   

Histological type (Poorly, Mucinous)

1.251

0.533-2.940

0.607

1.735

0.667-4.513

0.259

Detection of unresectable tumor (Metachronous)

0.653

0.327-1.304

0.227

   

Distant metastasis except peritoneal dissemination (Yes)

0.684

0.271-1.726

0.421

   

Peritoneal dissemination (Yes)

1.411

0.771-2.582

0.264

1.888

0.641-5.561

0.249

The number of organs affected by metastasis (≥2)

1.054

0.602-1.847

0.853

0.488

0.184-1.291

0.148

Pretreatment CEA (>5 ng/ml)

1.385

0.590-3.253

0.455

   

Pretreatment CA19-9 (>37 U/ml)

1.619

0.900-2.913

0.108

   

Molecular targeted therapy (Yes)

0.751

0.432-1.306

0.310

   

Cholinesterase (<235 IU/l)

0.915

0.289-2.890

0.879

   

Cholesterol (<200 mg/dl)

1.180

0.408-3.406

0.760

   

NLR (>2.8)

2.639

1.383-5.035

0.003

2.457

1.165-5.182

0.018

GPS (2)

2.558

0.900-7.269

0.078

1.237

0.466-3.287

0.670

AGR (>1.25)

1.946

1.033-3.668

0.039

2.247

1.069-4.722

0.033

  1. CI: confidence interval, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19–9, AGR: albumin to globulin ratio, NLR: neutrophil to lymphocyte ratio, GPS: Glasgow prognostic score, AGR: albumin to globulin ratio.